BioSim renews the composition of its Board of Directors for a two-year term.
The General Assembly of the Spanish Association of Biosimilar Medicines - BioSim has proceeded to the statutory renewal of its representatives on the Board of Directors, who are appointed for a period of two years.
He has been re-elected as president of the Association Joaquín Rodrigo, on behalf of Sandoz, who has held this responsibility since the creation of BioSim in 2015, and was renewed in 2017.
The Vice Presidency has fallen to Pfizer (Concha Serrano), who joins this task; in the secretariat renews his mandate Mylan (Javier Anitua); and in the Treasury is incorporated R (Pedro Carter).
The vowels have fallen to Amgen (Maria Fernandez), Biogen (Raul Jimenez), Kern Pharma (Pepa Martinez), Lilly (Teresa Millan) y mAbxience (Susana Millan).
Composition of the New Board of Directors.
The new Biosim Board of Directors has been constituted as follows: